DiagnosDGNOF +1.00%16 Market Cap is $21.63 Mil as of Jul. 04, 2026. GuruFocus rates DGNOF with a GF Score™ of 16/100 and a GF Value™ of $0.05 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 695 Healthcare Providers & Services companies, Diagnos ranks worse than 73.96% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Diagnos's share price for the quarter that ended in Mar. 2026 was $0.1929. Diagnos's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 120.41 Mil. Therefore, Diagnos's market cap for the quarter that ended in Mar. 2026 was $23.23 Mil.
Diagnos's quarterly market cap
increased
from Sep. 2025 ($22.12 Mil) to Dec. 2025 ($31.57 Mil) but then
declined
from Dec. 2025 ($31.57 Mil) to Mar. 2026 ($23.23 Mil).
Diagnos's annual market cap
increased
from Mar. 2024 ($13.41 Mil) to Mar. 2025 ($20.68 Mil) and
increased
from Mar. 2025 ($20.68 Mil) to Mar. 2026 ($23.23 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Diagnos's Enterprise Value for Today is $21.26 Mil.
Diagnos (OTCPK:DGNOF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Diagnos Market Cap Related Terms
Diagnos Market Cap Historical Data
* Premium members only.
The historical data trend for Diagnos's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Diagnos's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diagnos Market Cap vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Diagnos's Market Cap distribution charts can be found below:
* The bar in red indicates where Diagnos's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Diagnos's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diagnos (DGNOF) has a Market Cap of $21.63 Mil as of Jul. 04, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Diagnos and its competitors. According to the industry distribution chart, Diagnos ranks #514 out of 695 companies in the Healthcare Providers & Services industry, placing it in the top 74%.
Is Diagnos' Market Cap too high?
Diagnos' current Market Cap is $21.63 Mil. The Healthcare Providers & Services industry median Market Cap is 97.60. Diagnos' value of $21.63 Mil is 77.8% below this industry median. Based on the distribution chart, Diagnos ranks #514 out of 695 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Diagnos has a GF Score™ of 16/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Diagnos' Market Cap compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Diagnos ranks #514 out of 695 companies for Market Cap. This places Diagnos in the lower half of its industry. The industry median Market Cap is 97.60. Diagnos' value of $21.63 Mil is 77.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Healthcare Providers & Services company?
The median Market Cap among Healthcare Providers & Services companies is 97.60, based on 695 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diagnos's current Market Cap of $21.63 Mil is 77.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Diagnos and its competitors. For the Healthcare Providers & Services industry, the median Market Cap is 97.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diagnos's current Market Cap is $21.63 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diagnos stock overvalued right now?
Based on GuruFocus' analysis, Diagnos (DGNOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.05, compared to a current price of $0.18 — trading 253.9% above its estimated fair value. The current Market Cap is $21.63 Mil and 77.8% below the Healthcare Providers & Services industry median of 97.60. Diagnos' overall GF Score™ is 16/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Diagnos (DGNOF), the current Market Cap is $21.63 Mil as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diagnos (DGNOF) Overvalued in 2026?
Based on GuruFocus' analysis, Diagnos stock appears to be overvalued.
The current stock price of $0.18 is trading 253.9% above its estimated GF Value™ of $0.05.
GuruFocus considers Diagnos to be Significantly Overvalued.
Key valuation signals for DGNOF:
Market Cap: $21.63 Mil
GF Value™: $0.05 vs. price of $0.18 (253.9% above fair value)
Industry Position: 77.8% below the Healthcare Providers & Services median (#514 of 695)
No single metric tells the full story. See the DGNOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diagnos Inc is engaged in the provision of software-based interpretation services to assist health specialists in the detection of diabetic retinopathy. The company provides image analysis services through CARA (Computer Assisted Retinal Analysis). It operates in a single business segment of Healthcare services. The company has a business presence in Canada, United States of America, Mexico, Chile and others. The company's key revenue is derived from Canada.
16GF Score
Get the complete analysis for DGNOF
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DGNOF has been successfully added to your 
